EXEC: Evercore ISI Downgrades Nike on Another Potential Guidance Cut
Evercore ISI downgraded Nike to "In‑Line" and cut its price target to $46, down $11 from the prior $57. The firm trimmed FY26 earnings estimates to $1.65 and FY27 to $2.20, both below consensus forecasts. Weak wholesale sell‑through, rising order cancellations, limited pipeline innovation and expanding discounts have raised the risk of another guidance cut. Nike’s shares fell to $42.38, a sharp drop from the $63.71 start‑of‑year level, though solid performance categories and a $1 billion tariff refund could provide some support.
Jeremy Grantham: How to Invest Like a Stock Market Legend
Jeremy Grantham, famed bubble‑spotter, warned that today’s AI frenzy mirrors past market manias, from Japan’s 1980s bubble to the dot‑com crash. He singled out SpaceX’s AI‑laden prospectus as an example of speculative overreach, noting massive losses and uncertain revenue streams....
Sandisk Still Looks Investable After A Massive Rally
Sandisk Corp. posted a blockbuster Q3 2026, with revenue soaring 251% to $5.95 billion and gross margins hitting 78.4%, driven by a shift toward high‑value data‑center contracts. Multi‑year supply agreements now lock in roughly $42 billion of recurring revenue, while new HBF memory...
BlackBerry Has Morphed Into a 'Mission Critical' Player in Tech, Making It a Buy, Says Stifel
BlackBerry has reinvented itself as a mission‑critical software supplier for AI‑linked applications, centering on its QNX platform that underpins automotive, industrial, healthcare and robotics systems. Stifel initiated coverage with a buy rating and a $12 price target, implying roughly 36%...
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission
Conexeu Sciences (CNXU) is positioned as a buy on its patented CXU platform, which targets the fast‑growing regenerative‑medicine space, especially wound‑care. Its lead product, Ten‑Minute Tissue™, is slated for an FDA 510(k) submission by the first quarter of 2027, with...
REIT ETFs: Real Estate's Quiet Revival
REIT exchange‑traded funds are staging a notable comeback in 2026, driven by a 37% year‑to‑date surge in data‑center REITs and a flattening interest‑rate outlook. Schwab’s SCHH ETF crossed the $10 billion asset‑under‑management mark, while the equal‑weighted RDOG delivered a 15% total...